Bloomberg Radio Interview: Danish-American Partnering and Life Sciences Development Jonathan Gertler Posts, NewsBack Bay Life Science AdvisorsMay 8, 2018Bloomberg, Jonathan Gertler, Radio Interview
Back Bay Life Science Advisors to Lead Fireside Chat with Myovant Sciences President & Chief Executive Officer, Lynn Seely at Convergence Forum 2018 Events, Jonathan Gertler Postsjonathan gertlerApril 24, 2018Convergence Forum, Jonathan Gertler, Myovant
Back Bay Celebrates 8 Years and 450 Life Science Assignments Blog, Jonathan Gertler Posts, Newsjonathan gertlerApril 2, 2018Biotech, cross-border, Denmark, healthcare, Jonathan Gertler, Wall Street Journal, WSJ
Xconomy: Proxima Aims to Fill CRO Gap for Houston’s Growing Biotech Community Jonathan Gertler Posts, News, Back Bay in the Newsjonathan gertlerMarch 14, 2018Biotech, healthcare, Jonathan Gertler, Wall Street Journal, WSJ
Life Science Leader: Dynamics and Value of Cross-Border Biotech Jonathan Gertler Posts, NewsBack Bay Life Science AdvisorsMarch 1, 2018Biotech, cross-border, Denmark, healthcare, Jonathan Gertler, Wall Street Journal, WSJ
Fierce CEO: Back Bay Life Science Advisors CEO Helps Healthcare Companies Grow featured, Jonathan Gertler Posts, NewsBack Bay Life Science AdvisorsJanuary 29, 2018Biotech, healthcare, Jonathan Gertler, Wall Street Journal, WSJ
White Paper: US Biosimilars 2018: Opportunities and Challenges News, WhitepapersBack Bay Life Science AdvisorsJanuary 3, 2018Biotech, healthcare, Jonathan Gertler, Wall Street Journal, WSJ
Wall Street Journal Pro Venture Capital: Back Bay’s Jonathan Gertler Comments on Biotech IPO Market Jonathan Gertler Posts, NewsBack Bay Life Science AdvisorsOctober 3, 2017Biotech, healthcare, Jonathan Gertler, Wall Street Journal, WSJ
Wall Street Journal: Rise of Earnouts Muddies M&A Waters Jonathan Gertler Posts, NewsBack Bay Life Science AdvisorsAugust 30, 2017Biotech, healthcare, Jonathan Gertler, Wall Street Journal, WSJ
Precision Medicine and the Age of Collaboration Blog, Jonathan Gertler Posts, NewsBack Bay Life Science AdvisorsAugust 7, 2017Biotech, healthcare, Jonathan Gertler, Precision medicine
Boston Business Journal: A Potential Inflection Point for Biogen Jonathan Gertler Posts, NewsBack Bay Life Science AdvisorsJuly 20, 2017Biotech, Boston Business Journal, IPO, Jonathan Gertler
Boston Globe: The End of the IPO Drought Jonathan Gertler Posts, NewsBack Bay Life Science AdvisorsJuly 4, 2017Biotech, Boston Globe, IPO, Jonathan Gertler
Back Bay in the Boston Globe: Health Care Execs Could Lift GE’s Efforts in Life Sciences Back Bay in the NewsBack Bay Life Science AdvisorsJune 13, 2017Boston Globe, GE Healthcare, Jonathan Gertler
